Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Luisa L. Villa; Gonzalo Perez; Susanne K. Kjaer; Jorma Paavonen; Matti Lehtinen; Nubia Muñoz; Kristján Sigurdsson; Mauricio Hernandez-Avila; Finn Egil Skjeldestad; Steinar Thoresen; et al. (Profiled Author: Evan Robert Myers)
New England Journal of Medicine. 2007;356(19):1915-1927.Abstract
BACKGROUND: Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate a quadrivalent vaccine against HPV types 6, 11, 16, and 18 (HPV-6/11/16/18) for the prevention of high-grade cervical lesions associated with HPV-16 and HPV-18. METHODS: In this randomized, double-blind trial, we assigned 12,167 women between the ages of 15 and 26 years to receive three doses of either HPV-6/11/16/18 vaccine or placebo, administered at day 1, month 2, and month 6. The primary analysis was performed for a per-protocol susceptible population that included 5305 women in the vaccine group and 5260 in the placebo group who had no virologic evidence of infection with HPV-16 or HPV-18 through 1 month after the third dose (month 7). The primary composite end point was cervical intraepithelial neoplasia grade 2 or 3, adenocarcinoma in situ, or cervical cancer related to HPV-16 or HPV-18. RESULTS: Subjects were followed for an average of 3 years after receiving the first dose of vaccine or placebo. Vaccine efficacy for the prevention of the primary composite end point was 98% (95.89% confidence interval [CI], 86 to 100) in the per-protocol susceptible population and 44% (95% CI, 26 to 58) in an intention-to-treat population of all women who had undergone randomization (those with or without previous infection). The estimated vaccine efficacy against all high-grade cervical lesions, regardless of causal HPV type, in this intention-to-treat population was 17% (95% CI, 1 to 31). CONCLUSIONS: In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV-16 or HPV-18 than did those in the placebo group. Copyright © 2007 Massachusetts Medical Society.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Nubia Munoz; Susanne K. Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Cosette M. Wheeler; Gonzalo Perez; Darron R. Brown; Laura A. Koutsky; Eng Hseon Tay; et al.Journal of the National Cancer Institute. 2010;102(5):325-339.
Susanne K. Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Cosette M. Wheeler; Gonzalo Perez; Darron R. Brown; Laura A. Koutsky; Hseon Tay Eng; Patricia García; et al.Cancer Prevention Research. 2009;2(10):868-878.
Y.P. Bao; N. Li; J.S. Smith; You-Lin QiaoInternational Journal of STD and AIDS. 2008;19(2):106-111.
Appears in this Document